Renibus Presents Phase 2 Results on RBT-1, a First-in-Class Preconditioning Agent, at the American Society for Enhanced Recovery and Perioperative Medicine (ASER PM) 2023 Meeting
Renibus Presents Phase 2 Results on RBT-1, a First-in-Class [...]
Renibus Presents Phase 2 Results on RBT-1, a First-in-Class [...]
Renibus Therapeutics Announces $47 Million Financing to Advance Lead [...]
Renibus Therapeutics Announces Breakthrough Therapy Designation from US FDA for [...]
Renibus Reports Positive Final Results from Phase 2 Study [...]
Renibus Therapeutics Announces Presentation at 22nd Annual Needham Virtual [...]
Renibus Therapeutics Announces Presentation at Oppenheimer 33rd Annual Healthcare [...]
Renibus Therapeutics Announces Participation in the SVB Securities Global Biopharma [...]
Renibus Therapeutics Announces Oral Presentation on RBT-1 Phase 2 [...]
Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 [...]
Renibus Therapeutics Strengthens Leadership Team with Asha Ramdas as [...]